Search

Your search keyword '"Eichler, April F."' showing total 41 results
Start Over Author "Eichler, April F."
41 results on '"Eichler, April F."'

1. Phase 2 study of pembrolizumab in patients with recurrent and residual high-grade meningiomas

Author

Brastianos, Priscilla K., Kim, Albert E., Giobbie-Hurder, Anita, Lee, Eudocia Quant, Wang, Nancy, Eichler, April F., Chukwueke, Ugonma, Forst, Deborah A., Arrillaga-Romany, Isabel C., Dietrich, Jorg, Corbin, Zachary, Moliterno, Jennifer, Baehring, Joachim, White, Michael, Lou, Kevin W., Larson, Juliana, de Sauvage, Magali A., Evancic, Kathryn, Mora, Joana, Nayyar, Naema, Loeffler, Jay, Oh, Kevin, Shih, Helen A., Curry, William T., Cahill, Daniel P., Barker, Fred G., Gerstner, Elizabeth R., and Santagata, Sandro

Published
2022
Full Text
View/download PDF

2. Increase in tumor-associated macrophages after antiangiogenic therapy is associated with poor survival among patients with recurrent glioblastoma

Author

Lu-Emerson, Christine, Snuderl, Matija, Kirkpatrick, Nathaniel D, Goveia, Jermaine, Davidson, Christian, Huang, Yuhui, Riedemann, Lars, Taylor, Jennie, Ivy, Percy, Duda, Dan G, Ancukiewicz, Marek, Plotkin, Scott R, Chi, Andrew S, Gerstner, Elizabeth R, Eichler, April F, Dietrich, Jorg, Stemmer-Rachamimov, Anat O, Batchelor, Tracy T, and Jain, Rakesh K

Subjects
Cancer, Rare Diseases, Neurosciences, Brain Disorders, Brain Cancer, Adolescent, Adult, Aged, Aged, 80 and over, Angiogenesis Inhibitors, Antigens, CD, Autopsy, Biomarkers, Tumor, Brain Neoplasms, Female, Flow Cytometry, Follow-Up Studies, Glioblastoma, Humans, Immunoenzyme Techniques, Macrophages, Male, Middle Aged, Neoplasm Grading, Neoplasm Recurrence, Local, Prognosis, Survival Rate, Tumor Microenvironment, Young Adult, antiangiogenic therapy, glioblastoma, myeloid cells, relapse, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

Antiangiogenic therapy is associated with increased radiographic responses in glioblastomas, but tumors invariably recur. Because tumor-associated macrophages have been shown to mediate escape from antiangiogenic therapy in preclinical models, we examined the role of macrophages in patients with recurrent glioblastoma. We compared autopsy brain specimens from 20 patients with recurrent glioblastoma who received antiangiogenic treatment and chemoradiation with 8 patients who received chemotherapy and/or radiotherapy without antiangiogenic therapy or no treatment. Tumor-associated macrophages were morphologically and phenotypically analyzed using flow cytometry and immunohistochemistry for CD68, CD14, CD163, and CD11b expression. Flow cytometry showed an increase in macrophages in the antiangiogenic-treated patients. Immunohistochemical analysis demonstrated an increase in CD68+ macrophages in the tumor bulk (P < .01) and infiltrative areas (P = .02) in antiangiogenic-treated patients. We also observed an increase in CD11b+ cells in the tumor bulk (P < .01) and an increase in CD163+ macrophages in infiltrative tumor (P = .02). Of note, an increased number of CD11b+ cells in bulk and infiltrative tumors (P = .05 and P = .05, respectively) correlated with poor overall survival among patients who first received antiangiogenic therapy at recurrence. In summary, recurrent glioblastomas showed an increased infiltration in myeloid populations in the tumor bulk and in the infiltrative regions after antiangiogenic therapy. Higher numbers of CD11b+ cells correlated with poor survival among these patients. These data suggest that tumor-associated macrophages may participate in escape from antiangiogenic therapy and may represent a potential biomarker of resistance and a potential therapeutic target in recurrent glioblastoma.

Published
2013

5. Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation

Author

Batchelor, Tracy T., Gerstner, Elizabeth R., Emblem, Kyrre E., Duda, Dan G., Kalpathy-Cramer, Jayashree, Snuderl, Matija, Ancukiewicz, Marek, Polaskova, Pavlina, Pinho, Marco C., Jennings, Dominique, Plotkin, Scott R., Chi, Andrew S., Eichler, April F., Dietrich, Jorg, Hochberg, Fred H., Lu-Emerson, Christine, lafrate, A. John, Ivy, Percy, Rosen, Bruce R., Loeffler, Jay S., Wen, Patrick Y., Sorensen, Greg, and Jain, Rakesh K.

Published
2013

8. Early changes in glioblastoma metabolism measured by MR spectroscopic imaging during combination of anti-angiogenic cediranib and chemoradiation therapy are associated with survival

Author

Andronesi, Ovidiu C., Esmaeili, Morteza, Borra, Ronald J. H., Emblem, Kyrre, Gerstner, Elizabeth R., Pinho, Marco C., Plotkin, Scott R., Chi, Andrew S., Eichler, April F., Dietrich, Jorg, Ivy, S. Percy, Wen, Patrick Y., Duda, Dan G., Jain, Rakesh, Rosen, Bruce R., Sorensen, Gregory A., and Batchelor, Tracy T.

Published
2017
Full Text
View/download PDF

9. A phase I study of lapatinib with whole brain radiotherapy in patients with Human Epidermal Growth Factor Receptor 2 (HER2)-positive breast cancer brain metastases

Author

Lin, Nancy U., Freedman, Rachel A., Ramakrishna, Naren, Younger, Jerry, Storniolo, Anna Maria, Bellon, Jennifer R., Come, Steven E., Gelman, Rebecca S., Harris, Gordon J., Henderson, Mark A., MacDonald, Shannon M., Mahadevan, Anand, Eisenberg, Emily, Ligibel, Jennifer A., Mayer, Erica L., Moy, Beverly, Eichler, April F., and Winer, Eric P.

Published
2013
Full Text
View/download PDF

16. Pemetrexed in Recurrent or Progressive Central Nervous System Lymphoma: A Phase I Multicenter Clinical Trial

Author

Dietrich, Jorg, primary, Versmee, Laura, additional, Drappatz, Jan, additional, Eichler, April F., additional, Nayak, Lakshmi, additional, Norden, Andrew, additional, Wong, Eric, additional, Pisapia, Michelle R., additional, Jones, SooAe S., additional, Gordon, Amanda B., additional, Chabner, Bruce A., additional, Hochberg, Fred, additional, and Batchelor, Tracy T., additional

Published
2020
Full Text
View/download PDF

18. Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation

Author

Harvard University--MIT Division of Health Sciences and Technology, Rosen, Bruce R., Batchelor, Tracy T., Gerstner, Elizabeth R., Emblem, Kyrre E., Duda, Dan G., Kalpathy-Cramer, Jayashree, Snuderl, Matija, Ancukiewicz, Marek, Polaskova, Pavlina, Pinho, Marco C., Jennings, Dominique, Plotkin, Scott R., Chi, Andrew S., Eichler, April F., Dietrich, Jorg, Hochberg, Fred H., Lu-Emerson, Christine, Iafrate, A. John, Ivy, S. Percy, Loeffler, Jay S., Wen, Patrick Y., Sorensen, A. Greg, Jain, Rakesh K., Harvard University--MIT Division of Health Sciences and Technology, Rosen, Bruce R., Batchelor, Tracy T., Gerstner, Elizabeth R., Emblem, Kyrre E., Duda, Dan G., Kalpathy-Cramer, Jayashree, Snuderl, Matija, Ancukiewicz, Marek, Polaskova, Pavlina, Pinho, Marco C., Jennings, Dominique, Plotkin, Scott R., Chi, Andrew S., Eichler, April F., Dietrich, Jorg, Hochberg, Fred H., Lu-Emerson, Christine, Iafrate, A. John, Ivy, S. Percy, Loeffler, Jay S., Wen, Patrick Y., Sorensen, A. Greg, and Jain, Rakesh K.

Abstract

Antiangiogenic therapy has shown clear activity and improved survival benefit for certain tumor types. However, an incomplete understanding of the mechanisms of action of antiangiogenic agents has hindered optimization and broader application of this new therapeutic modality. In particular, the impact of antiangiogenic therapy on tumor blood flow and oxygenation status (i.e., the role of vessel pruning versus normalization) remains controversial. This controversy has become critical as multiple phase III trials of anti-VEGF agents combined with cytotoxics failed to show overall survival benefit in newly diagnosed glioblastoma (nGBM) patients and several other cancers. Here, we shed light on mechanisms of nGBM response to cediranib, a pan-VEGF receptor tyrosine kinase inhibitor, using MRI techniques and blood biomarkers in prospective phase II clinical trials of cediranib with chemoradiation vs. chemoradiation alone in nGBM patients. We demonstrate that improved perfusion occurs only in a subset of patients in cediranib-containing regimens, and is associated with improved overall survival in these nGBM patients. Moreover, an increase in perfusion is associated with improved tumor oxygenation status as well as with pharmacodynamic biomarkers, such as changes in plasma placenta growth factor and sVEGFR2. Finally, treatment resistance was associated with elevated plasma IL-8 and sVEGFR1 posttherapy. In conclusion, tumor perfusion changes after antiangiogenic therapy may distinguish responders vs. nonresponders early in the course of this expensive and potentially toxic form of therapy, and these results may provide new insight into the selection of glioblastoma patients most likely to benefit from anti-VEGF treatments., National Institutes of Health (U.S.) (Grant 1U01CA154601)

Published
2014

19. Vandetanib plus sirolimus in adults with recurrent glioblastoma: results of a phase I and dose expansion cohort study

Author

Chheda, Milan G., primary, Wen, Patrick Y., additional, Hochberg, Fred H., additional, Chi, Andrew S., additional, Drappatz, Jan, additional, Eichler, April F., additional, Yang, Daniel, additional, Beroukhim, Rameen, additional, Norden, Andrew D., additional, Gerstner, Elizabeth R., additional, Betensky, Rebecca A., additional, and Batchelor, Tracy T., additional

Published
2014
Full Text
View/download PDF

20. Abstract LB-339: Increase in tumor-associated macrophages (TAMs) after antiangiogenic therapy is associated with poor survival in recurrent glioblastoma (GBM) patients.

Author

Lu-Emerson, Christine, primary, Snuderl, Matija, additional, Kirkpatrick, Nathaniel D., additional, Goveia, Jermaine, additional, Taylor, Jennie, additional, Davidson, Christian, additional, Huang, Yuhui, additional, Riedemann, Lars, additional, Ivy, S. Percy, additional, Duda, G. Dan, additional, Ancukiewicz3, Marek, additional, Plotkin, Scott R., additional, Chi, Andrew, additional, Gerstner, Elizabeth R., additional, Eichler, April F., additional, Dietrich, Jorg, additional, Stemmer-Rachamimov, Anat O., additional, Batchelor, Tracy T., additional, and Jain, Rakesh K., additional

Published
2013
Full Text
View/download PDF

21. Randomized Controlled Trial of a Video Decision Support Tool for Cardiopulmonary Resuscitation Decision Making in Advanced Cancer

Author

Volandes, Angelo E., primary, Paasche-Orlow, Michael K., additional, Mitchell, Susan L., additional, El-Jawahri, Areej, additional, Davis, Aretha Delight, additional, Barry, Michael J., additional, Hartshorn, Kevan L., additional, Jackson, Vicki Ann, additional, Gillick, Muriel R., additional, Walker-Corkery, Elizabeth S., additional, Chang, Yuchiao, additional, López, Lenny, additional, Kemeny, Margaret, additional, Bulone, Linda, additional, Mann, Eileen, additional, Misra, Sumi, additional, Peachey, Matt, additional, Abbo, Elmer D., additional, Eichler, April F., additional, Epstein, Andrew S., additional, Noy, Ariela, additional, Levin, Tomer T., additional, and Temel, Jennifer S., additional

Published
2013
Full Text
View/download PDF

22. A video decision support tool for CPR in advanced cancer: A randomized controlled trial.

Author

Volandes, Angelo E., primary, Paasche-Orlow, Michael, additional, El-Jawahri, Areej, additional, Mitchell, Susan L., additional, Kemeny, Margaret, additional, Hartshorn, Kevan L., additional, Jackson, Vicki A., additional, Barry, Michael J, additional, Davis, Aretha Delight, additional, Lopez, Lenny, additional, Walker-Corkery, Elizabeth, additional, Chang, Yuchiao, additional, Epstein, Andrew S., additional, Bulone, Linda, additional, Misra, Sumathi, additional, Peachey, Matt, additional, Noy, Ariela, additional, Levin, Tomer, additional, Eichler, April F., additional, and Temel, Jennifer S., additional

Published
2012
Full Text
View/download PDF

23. Effects of cediranib, a VEGF signaling inhibitor, in combination with chemoradiation on tumor blood flow and survival in newly diagnosed glioblastoma.

Author

Gerstner, Elizabeth Robins, primary, Emblem, Kyrre E., additional, Chi, Andrew S., additional, Eichler, April F., additional, Hochberg, Fred, additional, Drappatz, Jan, additional, Quant, Eudocia Carmen, additional, Norden, Andrew David, additional, Pinho, Marco C, additional, Polaskova, Pavlina, additional, Jennings, Dominique, additional, Ancukiewicz, Marek, additional, Ivy, S. Percy, additional, Wen, Patrick Y., additional, Jain, Rakesh K., additional, Sorensen, A. Gregory, additional, and Batchelor, Tracy, additional

Published
2012
Full Text
View/download PDF

24. Phase I trial with biomarker studies of vatalanib (PTK787) in patients with newly diagnosed glioblastoma treated with enzyme inducing anti-epileptic drugs and standard radiation and temozolomide

Author

Gerstner, Elizabeth R., primary, Eichler, April F., additional, Plotkin, Scott R., additional, Drappatz, Jan, additional, Doyle, Colin L., additional, Xu, Lei, additional, Duda, Dan G., additional, Wen, Patrick Y., additional, Jain, Rakesh K., additional, and Batchelor, Tracy T., additional

Published
2010
Full Text
View/download PDF

25. Phase II Study of Cediranib, an Oral Pan–Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Recurrent Glioblastoma

Author

Batchelor, Tracy T., primary, Duda, Dan G., additional, di Tomaso, Emmanuelle, additional, Ancukiewicz, Marek, additional, Plotkin, Scott R., additional, Gerstner, Elizabeth, additional, Eichler, April F., additional, Drappatz, Jan, additional, Hochberg, Fred H., additional, Benner, Thomas, additional, Louis, David N., additional, Cohen, Kenneth S., additional, Chea, Houng, additional, Exarhopoulos, Alexis, additional, Loeffler, Jay S., additional, Moses, Marsha A., additional, Ivy, Percy, additional, Sorensen, A. Gregory, additional, Wen, Patrick Y., additional, and Jain, Rakesh K., additional

Published
2010
Full Text
View/download PDF

28. Leukodystrophies

Author

Costello, Daniel J., primary, Eichler, April F., additional, and Eichler, Florian S., additional

Published
2009
Full Text
View/download PDF

34. Recursive partitioning analysis of prognostic variables in newly diagnosed anaplastic oligodendroglial tumors.

Author

Panageas, Katherine S., Reiner, Anne S., Iwamoto, Fabio M., Cloughesy, Timothy F., Aldape, Kenneth D., Rivera, Andreana L., Eichler, April F., Louis, David N., Paleologos, Nina A., Fisher, Barbara J., Ashby, Lynn S., Cairncross, J. Gregory, Roldán Urgoiti, Gloria B., Wen, Patrick Y., Ligon, Keith L., Schiff, David, Robins, H. Ian, Rocque, Brandon G., Chamberlain, Marc C., and Mason, Warren P.

Published
2014
Full Text
View/download PDF

35. Initial treatment patterns over time for anaplastic oligodendroglial tumors.

Author

Panageas, Katherine S., Iwamoto, Fabio M., Cloughesy, Timothy F., Aldape, Kenneth D., Rivera, Andreana L., Eichler, April F., Louis, David N., Paleologos, Nina A., Fisher, Barbara J., Ashby, Lynn S., Cairncross, J. Gregory, Roldán Urgoiti, Gloria B., Wen, Patrick Y., Ligon, Keith L., Schiff, David, Robins, H. Ian, Rocque, Brandon G., Chamberlain, Marc C., Mason, Warren P., and Weaver, Susan A.

Published
2012
Full Text
View/download PDF

36. International retrospective study of over 1000 adults with anaplastic oligodendroglial tumors.

Author

Lassman, Andrew B., Iwamoto, Fabio M., Cloughesy, Timothy F., Aldape, Kenneth D., Rivera, Andreana L., Eichler, April F., Louis, David N., Paleologos, Nina A., Fisher, Barbara J., Ashby, Lynn S., Cairncross, J. Gregory, Roldán, Gloria B., Wen, Patrick Y., Ligon, Keith L., Schiff, David, Robins, H. Ian, Rocque, Brandon G., Chamberlain, Marc C., Mason, Warren P., and Weaver, Susan A.

Published
2011
Full Text
View/download PDF

38. Response to Weltman and Fleury Malheiros, re Lassman et al.

Author

Lassman, Andrew B., Iwamoto, Fabio M., Cloughesy, Timothy F., Aldape, Kenneth D., Rivera, Andreana L., Eichler, April F., Louis, David N., Paleologos, Nina A., Fisher, Barbara J., Ashby, Lynn S., Cairncross, J. Gregory, Roldán Urgoiti, Gloria B., Wen, Patrick Y., Ligon, Keith L., Schiff, David, Robins, H. Ian, Rocque, Brandon G., Chamberlain, Marc C., Mason, Warren P., and Weaver, Susan A.

Published
2012
Full Text
View/download PDF

39. INCREASED PERFUSION DUE TO VASCULAR NORMALIZATION IMPROVES OXYGENATION AND SURVIVAL IN GLIOBLASTOMA PATIENTS TREATED WITH CEDIRANIB WITH OR WITHOUT CHEMORADIATION.

Author

Batchelor, Tracy T., Gerstner, Elizabeth R., Emblem, Kyrre E., Duda, Dan G., Kalpathy-Cramer, Jayashree, Snuderl, Matija, Ancukiewicz, Marek, Polaskova, Pavlina, Pinho, Marco C., Jennings, Dominique, Plotkin, Scott R., Chi, Andrew S., Eichler, April F., Dietrich, Jorg, Hochberg, Fred H., Lu-Emerson, Christine, Iafrate, A. John, Ivy, S. Percy, Rosen, Bruce, and Loeffler, Jay S.

Published
2014
Full Text
View/download PDF

40. Brain metastases.

Author

Lu-Emerson C and Eichler AF

Subjects
Brain Neoplasms diagnosis, Brain Neoplasms therapy, Humans, Prognosis, Brain Neoplasms secondary, Neoplasm Metastasis diagnosis, Neoplasm Metastasis physiopathology, Neoplasm Metastasis therapy
Abstract

Purpose of Review: Brain metastases are the most common neurologic complication related to systemic cancer. With continued improvements in systemic treatment, the incidence is expected to increase. This article reviews the clinical presentation, pathophysiology, prognostic factors, and treatment of metastatic brain tumors., Recent Findings: Brain metastases from systemic cancer are up to 10 times more common than primary malignant brain tumors and are a significant burden in the management of patients with advanced cancer. Common presenting symptoms include headache, focal weakness or numbness, mental status change, and seizure. Management and treatment of metastatic brain tumors is complex and dependent on several factors, including age, performance status, number of metastases at presentation, and status of systemic disease. At the time of diagnosis, most patients have more than one brain metastasis, and treatment has traditionally consisted of whole-brain radiation therapy (WBRT). For those patients with single brain metastases, aggressive local treatment with surgery or stereotactic radiosurgery (SRS) combined with WBRT has been shown to improve survival and neurologic outcomes compared with WBRT alone. In patients with a limited number of brain metastases, SRS alone is being increasingly explored as a treatment option that spares the upfront toxicity of WBRT. Currently, the role of chemotherapy is limited to experimental settings and salvage after radiation therapy., Summary: Patients with brain metastases have complex needs and require a multidisciplinary approach in order to optimize intracranial disease control while maximizing neurologic function and quality of life. Patients with multiple metastases, uncontrolled systemic disease, and poor functional status are typically treated with WBRT alone, whereas surgery and SRS may be used for additional local control in a subset of patients with fewer tumors and good functional status. The incorporation of neuropsychological outcomes, neurologic function, and quality of life as end points in future studies will offer further guidance for providing comprehensive care to patients with metastatic brain tumors.

Published
2012
Full Text
View/download PDF

41. Leukodystrophies: classification, diagnosis, and treatment.

Author

Costello DJ, Eichler AF, and Eichler FS

Subjects
Age of Onset, Diagnostic Imaging methods, Humans, Hereditary Central Nervous System Demyelinating Diseases classification, Hereditary Central Nervous System Demyelinating Diseases diagnosis, Hereditary Central Nervous System Demyelinating Diseases therapy, Nerve Fibers, Myelinated pathology
Abstract

Background: The leukodystrophies are a heterogeneous group of diseases, which primarily affect white matter. Symptomatic patients are frequently misdiagnosed and the leukodystrophies are collectively under recognized. However, with ongoing research and increased availability of neuroimaging, our understanding of these diseases is increasing at a steady rate. Recent advances in the diagnosis and treatment of certain forms of leukodystrophy should prompt increased awareness of these diseases in clinical practice., Review Summary: The clinical features, pathophysiology, and therapeutic approach to these diseases are described. Particular emphasis is placed on genetic and pathophysiologic mechanisms, imaging patterns, screening of other family members and, where available, treatment options and resources., Conclusions: With more widespread use of neuroimaging, both pediatric and adult neurologists will increasingly be confronted with white matter disorders. Neurologists should have an approach to the recognition, diagnosis, and management of white matter diseases in general and the leukodystrophies in specific.

Published
2009
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results